ClinicalTrials.gg
RecruitingNCT06501053CORRECTUpdated Aug 10, 2026

Contact Radiotherapy for Rectal Cancer

An interventional study of Radiotherapy and Short-course radiotherapy in Rectal Cancer, sponsored by Alexander Valdman. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Alexander Valdman · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.

Planned enrollment
26th of 40
110 · median 233
Started
2025
with 3 others
No phase
20 of 64
10 open now
Primary completion
2030-04
later than 21 of 21 live
Registered
59th of 64
by date
Lead sponsor
2 of 64
Alexander Valdman

Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 26th largest by planned enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2025, is one of 20 with no phase, reaches primary completion later than 21 of the 21 other live ones, and was the 59th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Rectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

The aim of the CORRECT phase 2 study is to show non-inferiority of Contact x-ray brachytherapy (CXB) + short-course radiotherapy (SCRT) compared to the experimental arm of the OPERA trial in organ preservation for early and early intermediate rectal cancer (cT1-3abN1).

Read the detailed description

The primary aim of this study is to determine whether a combination of CXB + SCRT is non-inferior to CXB + chemoradiotherapy (CRT) regarding the primary endpoint 2-year organ preservation rate. Additionally, we hypothesize that a chemotherapy-free, radiation-only experimental treatment CXB+SCRT is associated with less side-effects compared to the OPERA regime.

In the OPERA trial (Gerard et al, 2023), the CXB was delivered in combination with long-course CRT. A combination of short-course radiotherapy (SCRT) and CXB has previously been used mainly in elderly and comorbid patients not suitable for long-course chemoradiotherapy. Recently, an international multi-institution report showed good outcomes of planned organ preservation using SCRT together with contact brachytherapy boost. However, no randomized data on this combination therapy are available. There are further no trials comparing CRT+CXB and SCRT+CXB.

Study participants will be randomized to either the standard treatment consisting of CXB (90Gy/3 fractions/4 weeks) and CRT 45/50 Gy (1.8/2 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (900 mg/m2 bid, on radiation days) OR the experimental treatment consisting of CXB (90Gy/3 fractions/4 weeks) SCRT (25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days).

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • organ sparing
  • brachytherapy
  • radiotherapy
  • nonoperative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the rectum classified as:
  • cT1-cT3ab, \< 5 cm largest diameter and \< ½ circumference (MRI staging), N0-N1 (\<= 3 nodes \< 8mm diameter), M0
  • Performance status () 0-1
  • Operable patient
  • Tumor accessible to endocavitary contact X-ray brachytherapy with a distance from the lower tumor border to the anal verge ≤10 cm
  • 18 years or above
  • No comorbidity preventing treatment
  • Patient having read the information note and having signed the
  • Follow-up possible

Exclusion criteria

Exclusion Criteria:

  • Inoperable patient
  • T3cd, T4, T≥ 5cm, Involvement of more than half of the bowel circumference
  • Distance from the lower tumor border to the anal verge >10 cm
  • N2-status at diagnosis or N1 with any node>= 8 mm diameter
  • Patient presenting with at diagnosis (M1)
  • Previous pelvic irradiation
  • Tumor with extramural vascular invasion
  • Poorly differentiated tumor
  • Simultaneous progressive cancer
  • Tumor invading external anal sphincter or growth within 1 mm of the levator
  • Tumor within 1 mm from MRF (mesorectal fascia)
  • Patient unable to receive CXB or CRT
  • Any significant concurrent medical illness that in the opinion of the investigator would preclude protocol therapy
  • Patient with history of poor compliance or current or past psychiatric conditions or severe acute or chronic medical conditions that would interfere with the ability to comply with the study protocol
  • Concurrent enrolment in another clinical trial using an anti-cancer treatment within 28 days prior to the first dose of study treatment
  • Total DPD deficiency
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    CXB + CRT

    Contact x-ray brachytherapy (CXB) (90Gy/3 fractions/4 weeks) and chemoradiotherapy (CRT) 45/50 Gy (1.8/2 Gy/fraction/5 weeks) with concurrent chemotherapy using capecitabine (900 mg/m2 bid, on radiation days).

    Radiation: Radiotherapy · Radiation: Contact x-ray brachytherapy · Drug: Chemotherapy

  • Experimental
    CXB + SCRT

    Contact x-ray brachytherapy (CXB) (90Gy/3 fractions/4 weeks) and a short-course radiotherapy (SCRT) (25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days).

    Radiation: Short-course radiotherapy · Radiation: Contact x-ray brachytherapy

Interventions

  • RadiationRadiotherapy

    45/50 Gy (1.8/2 Gy/fraction/5 weeks)

  • RadiationShort-course radiotherapy

    25 Gy in 5 daily fractions over a total time of 1 week, treating 5 days per week, 1 fraction per day, using 5 Gy per fraction, over the maximum treatment period of eight calendar days

  • RadiationContact x-ray brachytherapy

    90Gy/3 fractions/4 weeks

  • DrugChemotherapy

    Capecitabine (900 mg/m2 bid, on radiation days)

06

What researchers measure

Primary outcomes

  1. Rectum preservation

    Proportion of patients with successful rectum preservation after standard vs experimental treatment. Organ preservation is considered to have failed if the rectum is removed OR if the patient develops non-salvageable locoregional failure

    Time frame: At 24 months after start of treatment

Secondary outcomes

  1. Acute treatment-related toxicity

    Incidence of grade 3-5 toxicity as assessed by CTCAE v5.0

    Time frame: From start of treatment until 90 days after ending treatment

  2. Late treatment related toxicity

    Incidence of grade 3-5 toxicity as assessed by CTCAE v5.0

    Time frame: From 90 days after ending treatment until end of study

  3. Clinical complete response (cCR)

    Proportion of patients with cCR as assessed by DRE, endoscopy, MRI-T2W, and MRI-DWI

    Time frame: At 14-16 and 24-26 weeks after start of treatment

  4. Postoperative complications

    Difference in postoperative complications (graded according to Clavien-Dindo) after standard vs experimental treatment

    Time frame: Within the first 30 days after Total Mesorectal Excision (TME) surgery

  5. Stoma

    Proportion of patients with a stoma

    Time frame: At 12 and 24 months after start of treatment

  6. Metastasis-free survival

    Survival without sign of metastasis after standard vs experimental treatment

    Time frame: At 24 months after start of treatment

  7. Locoregional failure

    Proportion of patients with locoregional failure after standard vs experimental treatment

    Time frame: At 24 months after start of treatment

  8. Overall survival

    Overall survival after standard vs experimental treatment

    Time frame: At 24 months after start of treatment

  9. TME-free survival

    Survival without Total Mesorectal Excision after standard vs experimental treatment

    Time frame: At 24 months after start of treatment

  10. Salvage TME resections

    Rate of R0 Total Mesorectal Excisions after standard vs experimental treatment

    Time frame: From 24 weeks after start of treatment until end of study

  11. Tumor regression grade

    Tumor regression grade in the surgical specimen (R0, ypT0, ypTNM) after standard vs experimental treatment

    Time frame: After 14-16 weeks and 24-26 weeks after start of treatment

  12. Sphincter preservation

    Rate of sphincter preservation after standard vs experimental treatment

    Time frame: At 24 months after start of treatment

  13. General Health Related Quality of Life (HR QoL)

    General Health Related Quality of Life (HR QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire QLQ-C30. Responses made on a Likert scale are transformed to a score from 0 to 100 where a higher score indicate a better quality of life

    Time frame: At baseline and at 3, 6, 12, 24, 36, 48 and 60 months after start of treatment

  14. Colorectal cancer specific Health Related Quality of Life (HR QoL)

    Health Related Quality of Life (HR QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) colorectal cancer specific quality of life questionnaire QLQ-CR29. Responses made on a Likert scale are transformed to a score from 0 to 100 where a higher score indicate a better quality of life

    Time frame: At baseline and at 3, 6, 12, 24, 36, 48 and 60 months after start of treatment

  15. Bowel function

    Bowel function as assessed by the Low Anterior Resection Syndrome (LARS) score. LARS is scored from 0 to 42 points and a higher score indicates worse outcome.

    Time frame: At baseline, 3, 6, 12, 24, 36, 48 and 60 months after start of treatment

07

Study locations

2 of 2 sites recruiting
  • Karolinska University Hospital, Theme Cancer, Dept of Pelvic cancer
    Stockholm, Solna 171 76, Sweden
    Recruiting
  • Uppsala University Hospital, Colorectal Surgery
    Uppsala, 751 85, Sweden
    Recruiting
08

References and documents

Publications

  • Gerard JP, Barbet N, Schiappa R, Magne N, Martel I, Mineur L, Deberne M, Zilli T, Dhadda A, Myint AS; ICONE group. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):356-367. doi: 10.1016/S2468-1253(22)00392-2. Epub 2023 Feb 16. PubMed 36801007 ↗
  • Nilsson PJ, Folkesson J, Marsk R, Radu C, Stratulat I, Blomqvist L, Martling A, Valdman A. Contact radiotherapy for rectal cancer (CORRECT): study protocol for a multicentre randomised phase II trial. BMJ Open. 2025 Apr 9;15(4):e100356. doi: 10.1136/bmjopen-2025-100356. PubMed 40204311 ↗

Individual participant data

Plan to share: Yes — Anonymized individual participant data that underlie the reported results.

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by an independent review committee. A data-sharing agreement will also be required. Contact: alexander.valdman@ki.se

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2030, 61 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 61 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 15, 2024
StartActual
Mar 3, 2025
Primary completionEst.
Apr 2030
CompletionEst.
Nov 2032
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501053
Lead sponsor
Alexander Valdman
Collaborators
Uppsala University Hospital, Karolinska Institutet
Responsible party
Alexander Valdman (National Principal Investigator, Karolinska University Hospital) — Sponsor-investigator
First posted
Jul 15, 2024
Start date
Mar 3, 2025
Primary completion
Apr 2030 (estimated)
Completion
Nov 2032 (estimated)
Last update
Aug 10, 2026

Study contacts

Alexander Valdman, MD, PhD
Contact
alexander.valdman@regionstockholm.se
+46 70 002 13 17

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion